Sana Biotechnology

Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco, and Rochester.

  • NextGen Class of 2021
  • 2023 Best Places to Work
  • 2024 Best Places to Work
188 East Blaine Street, Suite 400
Seattle, WA 98102
  • Featured Employer Badge

We never lose sight of why our work matters – the potential to impact the lives of patients is important to everyone at Sana.

As we push the bounds of scientific discovery, we recognize there will be obstacles and setbacks, but we remain resilient in pursuit of our mission. We are looking for relentless individuals to join us and make this big vision a reality.

Our values are what ground us, keep our team connected, and make it possible for us to do our best work.

Lead from every seat.

We have a humble and unrelenting commitment to deliver for patients and our community – we seek to understand, act with honesty, and engage in the crucial conversations.

Thrive as a team.

We make each other better than we ever thought possible – we hire amazing people, are intensely curious, and cultivate inclusion and personal connectivity.

Make it happen.

We make great choices with urgency and integrity – we value vigorous debate, alignment around our decisions, and resilient execution.

At Sana, we believe that a diverse workforce strengthens us as a company and a community, which is essential for us to meaningfully change outcomes for patients across a wide range of diseases. We strive daily to make Sana an inclusive environment that attracts diverse talent and enables all people to thrive. Inclusion, diversity, and equity are key pillars in our overall strategy.

One of our core cultural tenets is that we make each other better than we ever thought possible. We want Sana to be the place for uniquely talented people to bring their authentic selves to work with an equal opportunity to make an impact, develop their careers, and deeply and positively impact the lives of patients.

Learn more about our IDE Approach.

Sana is proud to offer comprehensive benefits programs to our valued employees and their eligible loved ones. We thoughtfully design our programs, coverage, and guidelines with the needs of our employees in mind. Our goal is to make available a diverse offering of health and well-being resources and support so that employees can thrive and do the best work of their lives.

Learn more about Sana’s Benefits.

Sana Scholars is our internship and co-op program, seeking students who share in our passion for developing engineered cells as medicines and who believe that they have the potential to meaningfully change outcomes for patients across a broad swath of diseases. Sana Scholars also believe that building an inclusive, diverse, and equitable work environment will improve our probability of success in achieving this vision. We anticipate recruitment for this program in 2025.
Learn more about Sana Scholars.

“The most successful companies recognize that great people hire great people, great people acquire and develop great technologies, and finally, great people attract great capital. Sana’s success is dependent upon attracting and retaining the best people.”
Steve Harr, M.D., President and Chief Executive Officer
NEWS
The cash just keeps coming for biopharma companies. Here’s a rundown of some of this week’s investment dollar recipients.
Sana Biotechnology led the way with a very large initial public offering that could bring the company’s market value to $4.6 billion or more. But it’s not the only IPO this week. Here’s a look.
A recap of where life sciences cash has been flowing the past week.
The Seattle, Wash.-based biotech company says it will raise the funds by offering 15 million shares at $20 to $23 per share.
Despite its lofty valuation, the company does not yet have any drugs in the clinic, although it expects to submit Investigational New Drug applications in 2022 and 2023.
Biopharma companies raking in the cash with investment rounds and IPO announcements.
Sana Biotechnology has filed with the U.S. Securities and Exchange Commission to raise up to $150 million in an initial public offering to help support the company’s cell-based therapy discovery and development operations.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
JOBS
IN THE PRESS